BioMedNewsBreaks — VolitionRx Limited (NYSE American: VNRX) Highlights Latest Achievements in Mid-Year Review

Company: VolitionRx Limited. (VNRX)
Category: News

 

VolitionRx Limited (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, has released a mid-year review that highlights significant milestones, such as the expansion of the Nu.Q(R) Vet Cancer Test, which is now available for purchase in 15 countries. Additionally, Volition is engaged in active commercial discussions with significant players in the fields of liquid biopsy and in vitro diagnostics (“IVD”), for sepsis, and oncology.

Cameron Reynolds, President and Group Chief Executive Officer of Volition, emphasized the successful support provided to veterinary licensing and distribution partners to launch the Nu.Q(R) Vet Cancer Test . The company has also advanced its Nu.Q(R) NETs product for sepsis, Nu.Q(R) Lung Cancer, and Capture-PCR(TM) technologies, positioning them for licensing. Reynolds noted the substantial study data nearing readiness for inclusion in the data rooms and the interest from key industry players.

The company remains committed to its mission of developing cost-effective blood tests for diagnosing and monitoring various diseases in humans and animals while further strengthening its intellectual property portfolio that represents several significant commercial opportunities ready for commercialization through licensing. Looking ahead to the second half of 2024, Volition will focus on negotiating its first licensing deal in the human health space.

To learn more about Volition’s achievements, please read the full mid-year review at the following link: https://ibn.fm/e4JkH

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050